Search our database for opportunities and submit requests for additional information.
Our Policies

On this page you will find information about Stanford policies on:

Intellectual Property:
Stanford's policies regarding intellectual property are contained in the Research Policy Handbook.

Stanford is an ardent supporter of the licensing approach described in:
In the Public Interest: Nine Points to Consider in Licensing University Technology

top of page

Licensing Faculty-Associated Companies
OTL must be particularly sensitive to public perception when a potential licensee is a faculty-associated company. While faculty-inventor input is important in licensing decisions, OTL is aware of the faculty-inventor's potential conflicts of interest and must negotiate from an "arms-length" relationship. License agreements with faculty associated companies must meet the highest standards with respect to financial terms and diligence requirements to ensure that Stanford is justified in granting rights to the technology.

top of page

Material Transfer Agreements (MTAs)

Incoming Material Transfer Agreements
Information about MTAs for materials being sent to Stanford from industry is available from the Industrial Contracts Office.

Outgoing Material Transfer Agreements
Stanford and OTL have endorsed a policy regarding the distribution of tangible research materials. This policy encourages faculty and others to provide materials with no additional paperwork when they distribute materials as part of a sponsored research agreement or to their colleagues in academia and non-profit institutions.

If a Stanford researcher plans to send materials to an industry colleague, OTL can help provide either:

  1. An MTA that restricts use of the materials to research or evaluation purposes only. This document should be signed by an authorized official of the company and by OTL; or
  2. A license agreement for commercialization of the materials.
top of page

Clinical Technology Assessment Agreements

Under Clinical Technology Assessment Agreements (CTAA's), a company will provide experimental drugs to a researcher who administers the drug to patients under a specific protocol. The protocol must be approved by the Human Subjects Panel and, in most cases, the FDA. The CTAA is conducted for the purpose of generating data to evaluate the safety and efficacy of the drug. In most cases, the drug is patented by the company.

Contracts for these studies are handled by the Office of Sponsored Research in conjunction with the Research Management Group. For more information on Clinical Trials at Stanford, contact the The Stanford Center for Clinical and Translational Education and Research, Spectrum.

top of page

Stanford Trademarks

For information on Stanford's Trademark Licensing Program, please contact the Director of Business Development at: or call (650) 723-3331.

top of page